VEGFA and age-related macular degeneration: Regarding clinical applications, AAV vectors expressing the sFLT01 fusion protein comprising the VEGF and the Fc portion of the human IgG1 showed good safety and tolerability in a phase I trial in 19 age-related macular degeneration (AMD) patients [257].